Snipr Biome
The company develops CRISPR-powered medicines designed to target and eliminate antibiotic-resistant bacteria. Its technology utilizes bacteriophages and engineered probiotics to deliver CRISPR components that selectively destroy specific bacterial strains while sparing the rest of the microbiome. The firm currently manages a pipeline of five products addressing various diseases, with programs ranging from early discovery to Phase 2 clinical trials.
Visit websiteCopenhagen, Denmark
Biotechnology
Healthcare
Pharmaceuticals
Life Sciences
Funding summary
- Total raised
- €78.0M
- Funding rounds
- 2
Investors in Snipr Biome
Investors on record for Snipr Biome. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Snipr Biome?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors